Mark Elliott Boulding Sells 3,019 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 3,019 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $69.48, for a total transaction of $209,760.12. Following the sale, the vice president directly owned 105,212 shares in the company, valued at approximately $7,310,129.76. The trade was a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Wednesday, February 18th, Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total value of $213,698.16.
• On Tuesday, February 17th, Mark Elliott Boulding sold 2,813 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.29, for a total value of $194,912.77.
• On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.93, for a total value of $180,330.02.
• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total value of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total transaction of $171,196.30.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $68.98 on Wednesday. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The firm has a 50 day moving average price of $74.67 and a two-hundred day moving average price of $68.45. The stock has a market cap of $5.71 billion, a P/E ratio of 8.91 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The business had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.PTC Therapeutics’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.85) EPS. Analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PTCT has been the subject of a number of analyst reports. Bank of America lowered their price objective on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada dropped their price target on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Friday. TD Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Finally, Morgan Stanley boosted their target price on shares of PTC Therapeutics from $90.00 to $92.00 and gave the company an “overweight” rating in a report on Monday. Ten research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, PTC Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $80.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Empowered Funds LLC acquired a new stake in PTC Therapeutics in the first quarter worth $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of PTC Therapeutics by 11.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock valued at $9,109,000 after buying an additional 18,504 shares during the period. AlphaQuest LLC increased its position in PTC Therapeutics by 337.7% in the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 6,102 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in PTC Therapeutics by 7.0% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 41,376 shares of the biopharmaceutical company’s stock worth $2,021,000 after buying an additional 2,701 shares during the period. Finally, Brighton Jones LLC bought a new position in PTC Therapeutics in the second quarter worth approximately $226,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.